Skip to content
The Nexus
BUSINESSJul 13 · 10:15 UTCSCMP WORLDJulie Zhang

China’s drug industry pivots to AI-powered candidates to drive next wave of deals

China's drug industry is shifting focus to AI-powered drug candidates to drive future deals, following record US$110 billion in cross-border transactions for innovative drugs in the first half of 2026. China accounts for 30% of globally developed new drugs, ranking second worldwide.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Lan GongtaopersonNational Medical Products AdministrationorganizationAI-powered candidatestopiccross-border dealstopicinnovative drugstopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting